Week in Review: Innovent Acquires GenFleet's KRAS G12C Oncology Candidate in $312 Million Deal

Deals and Financings   Suzhou Innovent acquired greater China rights to GenFleet's lead KRAS G12C oncology candidate in a $312 million agreement; Shenzhen Ionova Life Science completed a $100 million financing to support its novel targeted and immuno therapies for cancer; Jacobio, a Beijing-Shanghai pharma, made a $53 million investment in Boston-based Hebecell to develop stem cell-based natural killer cell therapies; NeuExcell Therapeutics, a Pennsylvania-Shanghai gene therapy company focused on neurodegenerative diseases, completed a $10+ million Series Pre-A round; ETERN of Shanghai closed a Series B funding to advance its Protein Phase Separation technology to discover candidates for undruggable targets; 4B Technologies, a  Suzhou  biotech, will collaborate with  Hong Kong 's Insilico, an AI company, to develop small molecule therapies for ALS; Shanghai Microport EP Medtech and Stereotaxis of St. Louis will collaborate to develop advanced robotic electophysiology devices for cardiac ablation;   Trials and Approvals   Gloria, a Guangzhou biotech, was approved to launch its anti-PD-1 mAb in China to treat recurrent or refractory classical Hodgkin’s lymphoma; Arctic Vision of Shanghai was approved to start a China Phase III trial of a novel therapy for nearsightedness caused by age-related hardening of the lens;   Harbour BioMed was approved to start a China Phase II trial of its anti-inflammatory candidate for demyelinating polyneuropathy.  Stock Symbols: (HK: 01801) (HK: 1167) (HK: 02142) Share this with colleagues: // //